BiotechTube
HTD Biosystems

HTD Biosystems

San Francisco, United States· Est.
htdcorp.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $250K

Overview

HTD Biosystems is a private, established CRO/CDMO offering specialized formulation, lyophilization, and analytical services for complex biologics and novel drug delivery systems. The company leverages its expertise in protein characterization, vaccine development, and lipid-based nanoparticles to support clients in preclinical and early clinical development. Its value proposition centers on agility, technical innovation, and a collaborative approach, serving as a strategic partner for companies navigating the challenges of biopharmaceutical development.

ProteomicsDrug Discovery

Technology Platform

Integrated service platform for biologics formulation, lyophilization, and characterization, with specialized expertise in lipid nanoparticles (LNPs) and liposomal drug delivery systems.

Funding History

1
Total raised:$250K
Grant$250K

Opportunities

Strong demand for specialized formulation and manufacturing services for mRNA/LNP therapeutics and vaccines creates a significant growth tailwind.
The trend of biotech virtualization and outsourcing continues to expand the client base for nimble, expert CDMOs like HTD.

Risk Factors

Revenue is highly susceptible to biotech funding cycles.
Intense competition from larger CDMOs with broader capabilities and greater capital for investment poses a constant threat to market share and pricing power.

Competitive Landscape

HTD competes in a fragmented market against large, full-service CDMOs (e.g., Lonza, Catalent) and numerous smaller, niche CROs. Its differentiation is based on agility, deep expertise in specific complex modalities (LNPs, lyophilization), and a collaborative, client-focused service model.

More companies in Biologics / Biosimilars →More companies in United States →